Glomerulosclerosis: The Final Pathway Is Clarified, but Can We Deal with the Triggers??

Nephron

Volumn 73, Issue 1, 1996, Pages 1-7

  Wardle, Nigel ^a  

^a Oxford   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

NIPRADILOL; PENTOXIFYLLINE; PLATELET DERIVED GROWTH FACTOR; SIMVASTATIN; THROMBOXANE RECEPTOR BLOCKING AGENT; TRANSFORMING GROWTH FACTOR BETA; TRAPIDIL;

CAPILLARY; DIABETES CONTROL; DISEASE PREDISPOSITION; EDITORIAL; GLOMERULONEPHRITIS; GLOMERULOSCLEROSIS; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; METABOLIC DISORDER; PRIORITY JOURNAL; PROTEIN RESTRICTION; STRESS;

GLOMERULONEPHRITIS; GLOMERULOSCLEROSIS, FOCAL SEGMENTAL; HUMANS; TRANSFORMING GROWTH FACTOR BETA;

EID: 0029915150     PISSN: 16608151     EISSN: 22353186     Source Type: Journal    
DOI: 10.1159/000188990     Document Type: Article

References (112)

1. Klalir S, Schreiner G, Ichikawa I: Progression of renal disease., N Engl J Med 1988:318:1657-1666.
2. Jacobson HR: Chronic renal insufficiency: Pathophysiology., Lancet 1991;338:419-423.
3. Border WA, Rouslahti E: Transforming growth factor beta: The dark side of tissue repair., J Clin Invest 1992:90:1-7.
4. Border WA., Noble NA: From serum sickness tocytokines., Lab Invest 1993:68:125-128.
5. Border WA., Noble NA: Transforming growth factor beta in glomerular injury., Exp Nephrol 1994;2:13-17.
6. Bruijn JA., Roos A., de Geus B., de Hecr E: Transforming growth factor beta and the glomerular extracellular matrix in renal pathology., J Lab Clin Med 1994:123:34-47.
7. Appleton I., Tomlinson A, Colville-Nash PR., Willoughby DA: Temporal and spatial immu-nolocalisation of cytokines in murine chronic granulomatous tissue., Lab Invest 1993:69: 405-414.
8. Sasaki H, Pollard RB., Schmitt D., Suzuki F: Transforming growth factor beta in the regulation of the immune response., Clin Immunol Immunopathol 1992;65:1-9.
9. Tomooka S., Border WA, Marshall BC, Noble NA: Glomerular matrix accumulation is linked to inhibition of the plasmin protease system., Kidney Ini 1992;42:1462-1469.
10. Turner M., Chantry D., Katsikis P, Berger A., Brennan FM., Fcldmann M: Induction of the IL-I receptor antagonist by TGF beta., Eur J Immunol 1991;21:1635-1639.
11. Harlason MA: Extracellular matrix and growth factors., Lab Invest 1993:69:369-372.
12. Wilson HM., Reid JF., Brown P., et al: Effects of TGFbeta-l on plasminogen activators and PA1-1 in renal glomerular cells., Exp Nephrol 1993:1:343-350.
13. Habcrstroh U., Zahncr G., Thaiss F., Schoeppe W, Stahl RAK: Transforming growth factor beta induces bimodal effects on mesangial cell proliferation (abstract)., Kidney Int 1992:41: 483-484.
14. Haberstroh U., Zahner G, Disser M, Thaiss F., Wolf G., Stahl RAK: TGFbcta stimulates rat mesangial cell proliferation in culture: Role of PDGFbeta receptor expression., Am J Physiol 1993:264:F199-F205.
15. Roberts AB., Sporn MB: Physiologic actions and clinical applications of transforming growth factor beta., Growth Factors 1993:8:1-9.
16. Wrong JI., Attisano L, Wieser R., et al: Mechanism of activation of transforming growth factor beta receptor., Nature 1994:370:341-347.
17. MacKay K., Robbins AR., Bruce MD., Danicl-pour D: Identification ofTGF-p specific binding proteins in rat glomeruli., J BiolChem 1990; 265:9351-9356.
18. McKay K., Striker LJ., Stauffer J W, Doi T., Ago-do LY, Striker GE: Transforming growth factor beta: Murine glomerular receptors and responses of isolated glomerular cells., J Clin Invest 1989;83:1160-1167.
19. Nakamura T, Miller D., Ruoslahli W., Border WA: Production of extracellular matrix by glomerular epithelial cells is regulated by transforming growth factor beta-1., Kidney lnl 1992; 41:1213-1221.
20. Coimbra T, Wiggins R., Noli JW., Merritt S., Phan SH: TGFbeta production in anti-glomer-ular basement membrane disease in the rabbit., Am J Pathol 1991;138:223-224.
21. Okuda S., Languino LR., Ruoslahti E., Border WE: Elevated expression ofTGFbeta and proteoglycan production in experimental glomerulonephritis., J Clin Invest 1990;86:453-462.
22. Yamamoto T, Noble NA, Miller DE., Border WA: Sustained expression of TGF-P-1 underlies development of progressive kidney fibrosis., Kidney Int 1994;45:916-927.
23. Fukui M., Nakamura T., Ebihara I, Nagaoka I., Tomno Y, Koide H Low’ protein diet attenuates increased gene expression of PDGF and TGFoeta in experimental glomerulosclerosis., J Lab Clin Med 1993:121:224-234.
24. Jones CI., Buch S, Post M, McCulloch L, Liu E., Eddy A: Pathogenesis of interstitital fibrosis in chronic purine aminonucleosidc nephrosis., Kidney Int 1991;40:1020-1031.
25. Yamamoto T., Nakamura T, Noble NA, Ruoslahti E, Border WA: Expression ofTGFbeta is elevated in human and experimental diabetic nephropathy., Proc Natl Acad Sci USA 1993; 90:1814-1818.
26. Yoshioka K., Takcmura T, Murakami K., Okatia M., Hino S, Myasato H, Maki S: TGFbeta and mRNA in glomeruli in normal and diseased human kidneys., Lab Invest 1993:68: 154-163.
27. Border WA, Noble NA, Yamamoto T., Harper J, Picrschbacher MD., Ruoslahti E: Dccorin., a natural inhibitor of TGF beta, protects against scarring in experimental kidney disease., Nature: 992:360:361-364.
28. Yoshizumi M., Kurihara H., Sugiyama T., Taka-ku F., ct al: Hemodynamic shear stress stimulates endothelin production by cultured endothelial cells., Biochcm Biophys Res Commun 1989;160:93-100.
29. Morita T, Kurihara H, Macmura K., Yoshizumi H., Yazaki Y: Disruption of cytoskeletal structures mediates shear stress induced endothelin I gene expression in cultured porcine aortic endothelial cells., J Clin Invest 1993:92: 1706-1712.
30. Malck AM., Greene AI., Izumo S: Regulation of endothelin 1 gene by fluid shear sress is transcriptionally mediated and independent of protein kinase C and cyclic AMP., Proc Natl Acad Sci USA 1993:90:5999-6003.
31. Malek A., Gibbons M, Dzau VJ, Izumo S: Fluid shear stress differentially modulates expression of genes encoding basic FGF and PDGF-bcta chain in vascular endothelium., J Clin Invest 1993:92:2013-2021.
32. Garcia J, Patterson C., Bahlcr C., Aschner J., Hart CM., English D: Thrombin receptor activating peptides induce calcium ion mobilisation., barrier dysfunction, prostaglandin synthesis and PDGF messenger RNA expression in cultured endothelium., J Cell Physiol 1993:156: 541-549.
33. Cories P., Riser BI., Zhao X, Narins RG: Glomerular volume expansion and mesangial cell mechanical strain: Mediators of glomerular pressure injury., Kidney Int 1994:45(suppl 45): 11-16.
34. Sudhir K., Wilson E., Chalterjee K., Ives HE: Mechanical strain and collagen potentiate mitogenic activity of angiotensin II in rat vascular smooth muscle cells., J Clin Invest 1993,92: 3003-3007.
35. Riser BL, Corcts P., Zhao X., Bernstein J., Dum-ler F., Narins RG: Imraglomerular pressure and mesangial stretching stimulate extracellular matrix formation in the rat., J Clin Invest 1992; 90:1932-1943.
36. Homma T., Akai Y., Burns KD., Harris RC: Activation of S6 kinase by repealed cycles of stretching and relaxation in rat glomerular mesangial cells., J Biol Chem 1992,267:23129-23135.
37. Lin Y-C., Grinell F: Decreased level of PDGF stimulated receptor auto-phosphorylation by fibroblasts in mechanically relaxed collagen matrices., J Cell Biol 1993;122:663-672.
38. Wolf G, Haberstroh U., Ncilson EG: Angiotensin II stimulates the proliferation and biosynthesis of type 1 collagen in cultured murine mesangial cells., Am J Pathol 1992:141:95-107.
39. Kagami S., Border WA., Miller DE., Noble NA: Angiotensin II stimulates extracellular matrix protein synthesis through induction of TGFbe-ta in rat glomerular mesangial cells., J Clin Invest 1994:93:2431-2435.
40. Wolf G., Neilson EG: Angiotensin II as a renal cytokine., News Physiol Sci 1994;9:40-42.
41. Ketteler M., Noble NA., Border WA: TGFbeta and angiotensin II., Annu Rev Physiol 1995:57: 279-295.
42. Weber RT: Hormones and fibrosis: A case for lost reciprocal regulation., News Physiol Sci 1994:9:123-127.
43. Isaka Y., Fujiwara Y., Veda N., Kaneda Y., et al: Glomerulosclerosis induced by in vivo transfection of TGFbeta or PDGF gene into the rat kidney., J Clin Invest 1993:92:2597-2601.
44. Floege J, Johnson RJ., Gordon K., Iida H., Prit-zcl P., Yoshimura A., et al: Increased synthesis of extracellular matrix in mesangial proliferative nephritis., Kidney Int 1991:40:477-488.
45. Floege J., Eng E, Young BA, Johnson RJ: Factors involved in the regulation of mesangial cell proliferation in vitro and in vivo., Kidney Int 1993:43(suppl):47-54.
46. Floege J., Eng E., Young BA., Alpcrs CE., et al: Infusion of PDGF or basic FGF induces selective glomerular mesangial cell proliferation and matrix accumulation in rats., J Clin Invest 1993;92:2952-2962.
47. Cybulsky AV., Lieberthal W., Quigg RJ., Rennkc HG, Salant DJ: A role for thromboxane in complement mediated glomerular injury., Am J Pathol 1982:126:45-51.
48. Rothcr K., Hansch GM., Rauterberg EW: Complement in inflammation: Induction of nephritis and progression to chronicitv., Int Arch Allergy Appl Immunol 1991;94:23-27.
49. Wagner C., Braungcr M., Beer M., Rothcr K., Hansch GM: Induction of matrix protein synthesis in human glomerular mesangial cells by the terminal complement complex., Exp Nephrol 1994;2:51-56.
50. Wardle EN: Gl.omerulosclcrosis and lipid peroxidation., Nephron 1993:64:487.
51. Pares A., Potter JJ., Rennie I., Mczcry E: Acetaldehyde activates the promoter of the mouse a2(I) collagen gene., Hepatology 1994; 19:498-503.
52. Bruggcman I., Pellocoro J A., Horigan EA., Klot-man PE: Thromboxane and prostacyclin differentially regulate murine extracellular matrix gene expression., Kidnev Int 1993:43:1219-1225.
53. Kohan DE: Eicosanoids., potential regulators of extracellular matrix formation in the kidney., J Lab Clin Med 1993:120:4-6.
54. Rossi P., Karscntv G, Roberts AB., Roche NS., Sporn M., de Crombugghc B: A nuclear factor I binding site mediates the transcriptional activation ofatvpe I collagen promoter by TGFbeta., Cell 1988:52:405-414.
55. Morrow JD, Hill KE., Burk RF., Namour TM., Badr KE., Roberts LJ: A scries of prostaglandin Fj like compounds are produced in vivo by a non-cyclooxygenase free radical catalysed mechanism., Proc Natl Acad Sci USA 1990:87: 9383-9387.
56. Takahashi K., Namour TM., Fukinga M, ct al: Glomerular actions of a free radical generated novel prostaglandin 8 epiPGF2alpha in the rat: Evidence for interaction with thromboxane At receptors., J Clin Invest 1992;90:136-141.
57. McLaughlin GE., Frank L: Effects of 21 ami-nostcroid U74389Fon bleomycin induced pulmonary fibrosis in rats., Crit Care Med 1994: 22:313-319.
58. Parthasarathy S: Evidence for an additional intracellular site of action of probucol in the prevention of oxidative modification of low density lipoprotein., J Clin Invest 1992:89: 1618-1621.
59. l lirano T., Morchoshi T: Treatment of hvpcrli-pidacmia with probucol suppresses the development of focal and segmental glomerulosclerosis in chronic aminonuclcoside nephrosis., Nephron 1992:60:443-447.
60. Guijarro C., Keane WF: Lipid induced glomerular injury., Nephron 1994:67:1-6.
61. Suzuki S., Ebihara I., Tomino Y, Koide H:Tran-scriptional activation of matrix genes for TGF beta-1 in mesangial cells., Exp Nephrol 1993:1: 229-237.
62. Ding GH., Pesekdiamond I, Diamond JR: Cholestero I macrophages and gene expression of TGF beta-1 and fibronectin during nephrosis., Am.I Physiol 1993;264:F577-F584.
63. Singhal PC, Gupla S., Shen Z., Schlondorff D: Effects of PGE; and a thromboxane analogue on uptake of IgG complexes and LDL by mesangial cells., Am J Physiol 1991:261:F537-F544.
64. Granc EF., Abboud HE, Hohne M., Wall AK., et al: Actions of lipoproteins in cultured human mesangial cells., Am J Physiol 1992:263:F686-F696.
65. Rovin BH., Tan LC: LDL stimulates mesangial fibronectin production and chemoattractant expression., Kidney Int 1993:43:218-225.
66. Kim SB., Kang SA., Cho YJ., Park SK, el al: Effects of low-density lipoprotein on type IV collagen production by cultured rat mesangial cells., Nephron 1994;67:327-333.
67. Wheeler DC, Chana RS: Interactions between lipoproteins, glomerular cells and matrix., Miner Electrolyte Metab 1993:19:149-164.
68. Weisser B., Locher R., de Graaf J., Moser R, Sachinidis A., Vetter W: Low density lipoprotein subfractions increase thromboxane formation in endothelial cells., Biochem Biophys Res Commun 1993:192:1245-1250.
69. Takemura T., Yoshioka K., Aya N, et al: Apoli-poprateins and lipoprotein receptors in glomeruli in human kidney diseases., Kidney Int 1993: 43:918-927.
70. Keane WF., Kasiske BL, O’Donnell MP., Kim Y: Oxidised LDL increases mesangial cell expression of type IV collagen messenger RNA., J Am Soc Nephrol 1992:3:635.
71. Brownlee M, Cerami A., Vlassara H: Advanced glycosylation end-products in tissue and the biochemical basis of diabetic complications., N Engl J Med 1988;318:1315-1321.
72. Mukherjee B., Mukhcrjec JR, Chatterjee M: Lipid peroxidation, glutathione levels and changes in glutathione releated enzymes in streptozotocin induced diabetic rats., Immunol Cell Biol 1994:72:109-114.
73. Craven PA., Melhem MF., De Rubcrtis FR: Thromboxane in the pathogenesis of glomerular injury in diabetes., Kidney Int 1992:42:937-946.
74. Bollineni JS., Rcddi AS: TGF bcta-1 enhances glomerular collagen synthesis in diabetic rats., Diabetes 1993;42:1673-1677.
75. Cohen MP., Ziyadeh FN: Amadori glucose adducts modulate mesangial cell growth and collagen gene expression., Kidney Int 1994:45: 475-489.
76. Crowley ST., Brownlee M., Edelstcin D., Schlon-dorfl D: Effects of nonenzymatic glycosylation of mesangial matrix on proliferation of mesangial cells., Diabetes 1991;40:540-547.
77. Ledbetter S., Copeland EJ., Noonan D., Vogeli G, Hassell JR: Altered steady state messenger RNA levels of basement membrane proteins in diabetic mouse kidneys and thromboxane inhibition., Diabetes 1990;39:196-203.
78. Bourgoignic JJ: Progression of renal disease: Current concepts and therapeutic approaches., Kidney Int 1992:41 (suppl 36):61-65.
79. Heeg JE, de Jong PE, de Zeeuw D: Additive antiproteinuric effect of ACE inhibition and NSAID therapy., Clin Sci 1991:81:367-372.
80. Tepel M., Heidcnreich S., Zhu Z, Walter M., Nofer JR., Zidek W: C’aptopril inhibits the agonist induced increase of cytosolic free calcium ions in glomerular mesangial cells., Kidney Int 1994:46:696-702.
81. Couscr WG., Johnson RJ: Mechanisms of progressive renal disease in glomerulonephritis., Am J Kidney Dis 1994;23:193-198.
82. Lafayette RA., Mayer G., Park SK, Meyer TW: Angiotensin II receptor blockade limits glomerular injury in rats with reduced renal mass., J Clin Invest 1992;90:766-771.
83. Ishidoya S., Morrissey J., McCracken R., Reyes A., Klahr S: Angiotensin 11 receptor antagonist ameliorates renal tubulo-interstitial fibrosis caused by unilateral ureteric obstruction., Kidney Int 1995;47:1285-1294.
84. Remuzzi A., Bcnigni A., Malanchini B., Bruzzi I., Foglicni C, Remuzzi G: ACE inhibition prevents renal failure and death in unincphrcc-tomised MWF/Ztni rats., Kidney Int 1995:47: 1319-1326.
85. Bcnigni A., Zoja C, Corna D., Orisio S., Longa-retti K., Bertani T, Remuzzi G: A specific endo-thclin subtype A receptor antagonist protects against injury in renal disease progression., Kidney Int 1994:46:696-702.
86. Nakamura T., Ebihara I., Tomino Y., Koidc H: Effect of a specific endothclin A receptor antagonist on murine lupus nchritis., Kidney Int 1995:47:481-489.
87. Koya D., Kikkowa R., Heneda M., et al: Nipradi-lol inhibits rat mesangial cell mitogcncsis through activation of soluble guanylate cyclase., EurJ Pharmacol 1993:245:79-82.
88. Yohokawa K., Tahara H, Kohno M., Mandal SK, et al: Heparin regulates endothclin production through endothclin derived nitric oxide in human endothelial cells., J Clin Invest 1993:92: 2080-2085.
89. Cacnazzo C., Garbisa S., Ceol M., Baggio B, cl al: Heparin modulates proliferation and proteoglycan biosynthesis in murine mesangial cells., Nephrol Dial Transplant 1995:10:175-184.
90. Wardle EN: Altering the course of proliferative nephritidcs., J Int Med Res 1992:20:361-370.
91. Wardle EN: Advances in pharmacology and therapy of nephritidcs., Nephron 1994:66:129-135.
92. Remuzzi F., Fitzgerald GA., Patrono C: Thromboxane synthesis and action within the kidneys., Kidney Int 1993:41:1483-1493.
93. Lianos EA., Bresnahan BB., Wu S: Pathophysiologic role of eicosanoids in mesangial cell immune injury., J Lipid Mcdiat 1993:6:333-342.
94. Stahl R., Tltaiss F., Wenzel U., Schocppe W, Hclmchen A: A rat model of progressive glomerulosclerosis: The role of thromboxane inhibition., J Am Soc Nephrol 1992:2:1568-1577.
95. Zauner I., Bolhler J., Braun N., Grupp C., Hecr-ing P., Schollmever P: Effect of aspirin and dipyridamole on proteinuria in idiopathic membranoproliferative glomerulonephritis., Nephrol Dial Transplant 1994;9:619-622.
96. Belcher JD., Balia J., Balia G., et al: Vitamin F., supplements protect LDL and vascular endothelium from oxidative injury., Circulation 1993:88:563-567.
97. DeRubcrtis FR., Craven PA: Eicosanoids in the pathogenesis of the functional and structural alterations of the kidney in diabetes., Am J Kidney Dis 1993:22:727-735.
98. Das I., Khan NS., Sooranna SR: Potent activation of nitric oxide synthase by garlic., Curr Med Res Opin 1995:13:257-259.
99. Naito H., Hirano T: Probucol suppresses the development of chronic renal failure in Dahl salt sensitive rats: An animal model of spontaneous focal and segmental glomerulosclerosis., Nephron 1994:67:125-126.
100. Washio M., Narishi F., Okuda S., Onoyama K., Fujishima M: Alpha tocopherol improves focal glomerulosclerosis in rats with Adriaraycin induced progressive renal failure., Nephron 1994: 68:347-352.
101. Wardle EN: Vascular permeability in diabetes and its controI., Diabetes Res Clin Pract 1994:23:135-139.
102. Cohen MP., Sharma K., Jin Y, et al: Prevention of diabetic nephropathy in db/db mice with glycated albumin antagonists., J Clin Invest 1995:95:2338-2345.
103. Mullarkey CJ., Edelstcin D., Brownlee M: Free radical generation by early glycation products., Biochem Biophys Res Commun 1990; 173:932-939.
104. Magnusson A, Halldorsson H, Thorgcirsson G., Kjerd M: Endothclin secretion is regulated by cyclic AMP and phosphatase 2A in endothelial cells., J Cell Physiol 1994:161:429-434.
105. Gcrrero-Romano F, Rodriguez-Moran M., Paniagua-Sicrra JR., ct al: Pentoxifylline reduces proteinuria in insulin dependent and noninsulin dependent diabetic patients., Clin Nephrol 1995;43:116-121.
106. Tsai T-J, Lin R-H., Vhang C-C, et al: Vasodilator agents modulate rat glomerular mesangial cell growth and collagen synthesis., Nephron 1995;70:91-99.
107. Gradaliano G., Biswas P., Choudhury GC., Ab-boud HE: Simvastatin inhibits PDGF induced DNA synthesis in human glomerular cells., Kidney Int 1993;44:503-508.
108. Combe D., Deforges-Lassuer C, Caix J., Pom-mereau A, Marot D, Aparaicio M: Compliance and effcctsof nutritional treatment on progression and metabolic disorders of chronic renal failure., Nephrol Dial Transplant 1993:8:412-417.
109. Okuda S., Nakamura T., Yamamoto T., Ruos-lahti E., Border WA: Dietary protein restriction rapidly reduces TGFbcta-1 expression in experimental glomerulonephritis., Proc Natl Acad Sci USA 1991:83:9765-9769.
110. Gansevoort RT, de Zeeuw D., de Jong PE: Additive antiproteinuric effect of ACE inhibition and a low protein diet in human renal disease., Nephrol Dial Transplant 1995:10: 497-504.
111. Chan PC., Robinson JD, Yeung WC, Cheng I., et al: Lovastatin in glomerulonephritis patients with hyperlipidaemia and heavy proteinuria., Nephrol Dial Transplant 1992;7: 93-99.
112. O’Donnell MP., Kasiske BI., Kim Y., Schmitz PG., Keane WF: Lovastatin retards the progression of established glomerular disease in obese Zuckcr rats., Am J Kidney Dis 1993:22: 83-89.